MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-19-2025
OpGen EBITDA 2011-2026 | OPGN
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA OpGen
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 499 K | -29.4 M | -32.9 M | -20.6 M | -19.2 M | -10.1 M | -12.4 M | -14.6 M | -18.4 M | -13.9 M | -4.99 M | -8.72 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 499 K | -32.9 M | -15.4 M |
Quarterly EBITDA OpGen
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | -477 K | - | - | - | -1.7 M | - | -3.38 M | -4.97 M | -4.72 M | - | -13.3 M | -5.09 M | -5.33 M | - | -2.98 M | -4.85 M | -5.71 M | - | -4.55 M | -5.6 M | -3.77 M | - | -2.74 M | -2.13 M | -3.54 M | - | -2.72 M | -2.94 M | -2.86 M | - | -2.7 M | -3.87 M | -4.79 M | - | -4.31 M | -4.68 M | -4.31 M | - | -4.47 M | -2.85 M | -2.42 M | - | -1.44 M | -1.13 M | -1.03 M | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -477 K | -13.3 M | -3.79 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Diagnostics research industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Anixa Biosciences
ANIX
|
-11.7 M | $ 3.1 | 2.31 % | $ 101 K |  USA |
 |
Centogene N.V.
CNTG
|
-46 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Brainsway Ltd.
BWAY
|
-5 M | $ 24.05 | -2.67 % | $ 99.4 M |  Israel |
|
Akumin
AKU
|
70.1 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Aspira Women's Health
AWH
|
-32.5 M | - | -6.19 % | $ 10.5 M | USA |
 |
Biocept
BIOC
|
-30.3 M | - | -13.05 % | $ 7.29 M | USA |
 |
Castle Biosciences
CSTL
|
24.7 M | $ 39.16 | -0.89 % | $ 1.09 B | USA |
 |
Burning Rock Biotech Limited
BNR
|
-749 M | $ 33.54 | -5.15 % | $ 361 M |  China |
 |
Danaher Corporation
DHR
|
5.58 B | $ 219.62 | -2.19 % | $ 161 B | USA |
 |
Accelerate Diagnostics
AXDX
|
-12.3 M | - | -61.36 % | $ 2.46 M | USA |
 |
Exact Sciences Corporation
EXAS
|
-757 M | $ 102.3 | 0.05 % | $ 19 B | USA |
 |
Fulgent Genetics
FLGT
|
-49 M | $ 26.24 | -0.61 % | $ 793 M | USA |
 |
BioNano Genomics
BNGO
|
-90 M | $ 1.47 | -2.65 % | $ 1.87 M | USA |
 |
Guardant Health
GH
|
-401 M | $ 110.48 | 0.68 % | $ 13.6 B | USA |
 |
Check-Cap Ltd.
CHEK
|
-25.8 M | - | - | $ 9.42 M | Israel |
 |
Oxford Immunotec Global PLC
OXFD
|
-3.26 M | - | - | $ 562 M |  Britain |
 |
Chembio Diagnostics
CEMI
|
-21.1 M | - | 0.22 % | $ 16.8 M | USA |
 |
Co-Diagnostics
CODX
|
-41.5 M | - | - | $ 79.8 M | USA |
 |
DermTech
DMTK
|
-104 M | - | -11.32 % | $ 2.94 M | USA |
 |
Lantheus Holdings
LNTH
|
522 M | $ 66.68 | 0.56 % | $ 4.61 B | USA |
 |
Global Cord Blood Corporation
CO
|
652 M | - | - | $ 399 M | China |
 |
Fluidigm Corporation
FLDM
|
-35.1 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
-6 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
-518 M | - | 0.12 % | $ 80.1 M | China |
 |
PRA Health Sciences, Inc.
PRAH
|
416 M | - | - | $ 10.7 B | USA |
 |
DexCom
DXCM
|
784 M | $ 74.0 | 0.87 % | $ 28.6 B | USA |
 |
CareDx, Inc
CDNA
|
-189 M | $ 20.8 | 1.66 % | $ 1.12 B | USA |
 |
NeoGenomics
NEO
|
-53 M | $ 12.4 | 0.16 % | $ 1.57 B | USA |
 |
Celcuity
CELC
|
-113 M | $ 112.12 | -2.1 % | $ 4.42 B | USA |
 |
DarioHealth Corp.
DRIO
|
-55.7 M | $ 10.3 | -6.02 % | $ 292 M | Israel |
 |
Enzo Biochem
ENZ
|
-11.1 M | - | -8.98 % | $ 14.8 K | USA |
 |
Precipio
PRPO
|
-6.4 M | $ 24.26 | -1.98 % | $ 31.5 M | USA |
 |
Personalis
PSNL
|
-57.3 M | $ 9.97 | -0.2 % | $ 591 M | USA |
 |
Heska Corporation
HSKA
|
-6.33 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
-20.2 M | - | -20.0 % | $ 1.06 M | USA |
 |
Illumina
ILMN
|
-479 M | $ 149.69 | -0.11 % | $ 23.8 B | USA |
 |
QIAGEN N.V.
QGEN
|
301 M | - | - | $ 10.6 B |  Niderland |
 |
IQVIA Holdings
IQV
|
3.32 B | $ 235.62 | -1.73 % | $ 42.7 B | USA |
 |
Thermo Fisher Scientific
TMO
|
8.49 B | $ 592.16 | -2.61 % | $ 226 B | USA |
 |
Trinity Biotech plc
TRIB
|
6.62 M | $ 0.87 | -4.13 % | $ 61.9 M |  Irlanda |
 |
Charles River Laboratories International
CRL
|
589 M | $ 211.68 | -2.4 % | $ 10.9 B | USA |
 |
Twist Bioscience Corporation
TWST
|
-111 M | $ 41.58 | -1.02 % | $ 2.49 B | USA |
 |
Medpace Holdings
MEDP
|
475 M | $ 593.07 | -0.81 % | $ 18.4 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
1.84 B | $ 182.35 | -0.21 % | $ 20.2 B | USA |
|
Biodesix
BDSX
|
-28.7 M | $ 9.66 | -6.49 % | $ 1.25 B | USA |
 |
Motus GI Holdings
MOTS
|
-11.5 M | - | -34.28 % | $ 263 K | Israel |
 |
Laboratory Corporation of America Holdings
LH
|
1.73 B | $ 269.81 | 0.66 % | $ 22.6 B | USA |
 |
Mettler-Toledo International
MTD
|
50.4 M | $ 1 392.8 | -0.63 % | $ 29.6 B |  Schweiz |
 |
ICON Public Limited Company
ICLR
|
1.59 B | $ 185.89 | -0.23 % | $ 15.3 B | Irlanda |
 |
IDEXX Laboratories
IDXX
|
1.26 B | $ 676.71 | -1.6 % | $ 55.8 B | USA |